Aerie: A Brilliant Future, Derisking In Progress, And The Making Of A Major Ophthalmic Pharmaceutical
Northern Fundamentals - at Seeking Alpha - Tue Dec 23, 11:45AM CST
AGN: 210.12 (+0.95), VRX: 140.33 (-0.22), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), AERI: 29.49 (+1.23), NVS: 93.91 (+0.66)
Aerie Pharmaceuticals Added to NASDAQ Biotechnology Index (NBI)
Business Wire - Tue Dec 16, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that it has been selected for addition to the NASDAQ Biotechnology Index(R) (NASDAQ:^NBI), which will become effective upon market open on Monday, December 22, 2014.
IBB: 299.80 (+5.12), AERI: 29.49 (+1.23)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)
Spin Doctors; Data And Market Projections From Aerie Pharmaceuticals, Inc. Are Too Optimistic
Sirius Capital - Seeking Alpha - Fri Dec 12, 7:00AM CST
During the Cold War era there was a famous joke about a race between a US and a USSR runner in which the American crossed the finish line first. The headline in the Communist party newspaper 'Pravda' had read 'In an international race, the Soviet...
AERI: 29.49 (+1.23)
Aerie Pharma completes enrollment in Rhopressa Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 7:47AM CST
AERI: 29.49 (+1.23)
Aerie Pharmaceuticals Completes Enrollment in Phase 3 Registration Trial ("Rocket 1"
Business Wire - Tue Dec 02, 5:30AM CST
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today the completion of enrollment in the Company's 400-patient Phase 3 registration trial ("Rocket 1"
AERI: 29.49 (+1.23)
Aerie Pharmaceuticals to Present at the Piper Jaffray 26th Annual Healthcare Conference
Business Wire - Mon Nov 24, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Richard Rubino, chief financial officer, will present in a fireside chat discussion at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2, 2014 at 11:30 a.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update.
AERI: 29.49 (+1.23)
Aerie Pharmaceuticals to Present at the 2014 Stifel Nicolaus Annual Healthcare Conference
Business Wire - Wed Nov 12, 6:30AM CST
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., chairman and chief executive officer will present at the 2014 Stifel Nicolaus Annual Healthcare Conference on Tuesday, November 18, 2014 at 8:35 a.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
AERI: 29.49 (+1.23)
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 8:40PM CST
AERI: 29.49 (+1.23)
Aerie posts 3Q loss
Automated Insights - Tue Nov 11, 3:27PM CST
RESEARCH TRIANGLE PARK, N.C. (AP) _ Aerie Pharmaceuticals Inc. (AERI) on Tuesday reported a loss of $13.1 million in its third quarter.
AERI: 29.49 (+1.23)
Aerie Pharmaceuticals misses by $0.13
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:13PM CST
AERI: 29.49 (+1.23)
Aerie Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business and Product Development Update
Business Wire - Tue Nov 11, 3:05PM CST
--Rhopressa(TM) and Roclatan(TM) Development Programs Advancing
AERI: 29.49 (+1.23)
Aerie Pharma reports November 11
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:07AM CDT
AERI: 29.49 (+1.23)
Aerie Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014
Business Wire - Tue Oct 28, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its third quarter 2014 financial results will be released after the market closes on Tuesday, November 11, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and provide a general business update.
AERI: 29.49 (+1.23)
Aerie Pharmaceuticals names Dr Benjamin F. McGraw to board
M2 - Tue Oct 07, 7:01AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) revealed on Monday the addition of Benjamin F. McGraw, III, PharmD to its board of directors and as a member of its Audit Committee, effective 30 September 2014.
AERI: 29.49 (+1.23)
Aerie Pharmaceuticals Elects Benjamin F. McGraw, III to Its Board of Directors
Business Wire - Mon Oct 06, 3:45PM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that Benjamin F. McGraw, III, Pharm.D., has been elected to the Company's Board of Directors and as a member of the Audit Committee, effective September 30, 2014. Dr. McGraw brings more than 30 years of experience in the life sciences, responsible for advancing breakthrough technologies and numerous development-stage programs through commercialization.
AERI: 29.49 (+1.23)
Aerie Announces Closing of $125 Million Convertible Notes Financing
Business Wire - Tue Sep 30, 3:05PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has closed its $125 million financing with Deerfield Management Company L.P. ("Deerfield"
AERI: 29.49 (+1.23)
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
AERI: 29.49 (+1.23)
Aerie expects USD125m from convertible notes financing
M2 - Tue Sep 09, 6:42AM CDT
Pharmaceutical company Aerie Pharmaceuticals (NasdaqGM:AERI) revealed on Tuesday the receipt of a USD125m financing commitment from its current shareholder, Deerfield Management Company.
AERI: 29.49 (+1.23)